Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334879 · ClinicalTrials.gov registry record · Phase 1
High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
A Phase 1 study of Radiation Retinopathy, sponsored by The New York Eye Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01334879 is a Phase 1 study of Radiation Retinopathy that has completed, run by The New York Eye Cancer Center. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01334879, a Phase 1 study of Radiation Retinopathy, has completed, sponsored by The New York Eye Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.
Conditions Studied
Interventions
- DRUG ranibizumab 2.0 mg
Study Locations (1)
New York
- The New York Eye Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01334879
The ClinicalTrials.gov registry entry for NCT01334879 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye Cancer Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Radiation Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab 2.0 mg is the first listed.
NCT01334879 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01334879 about?
NCT01334879 is a clinical study titled "High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy". This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.
What is the current status of trial NCT01334879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2011-05. Estimated completion is 2012-11.
What conditions does trial NCT01334879 study?
This clinical trial studies the following conditions: Radiation Retinopathy.
What interventions are being tested in trial NCT01334879?
The interventions under investigation include: ranibizumab 2.0 mg (DRUG).
Who is sponsoring clinical trial NCT01334879?
This trial is sponsored by The New York Eye Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01334879 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.